India’s pillars of trust: CDSCO’s role in drug development and quality assurance
Rattachement africain : in. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
India’s pharmaceutical industry is a global beacon, delivering affordable medicines under the watchful eye of the Central Drugs Standard Control Organization (CDSCO). This narrative review dives into CDSCO’s world, exploring its structure, workforce, testing labs, licensing, certifications, exports, and challenges. Drawing from CDSCO reports, government documents, and recent analyses (2024-2025), it traces milestones like the 2019 New Drug and Clinical Trial (NDCT) Rules, 2024 Uniform Code of Pharmaceutical Marketing Practices (UCPMP), and 2025 biosimilars updates, showcasing India’s alignment with global standards. Despite strides, reliance on Chinese APIs poses risks. Recommendations include AI-driven monitoring, expanding local API production, and fostering partnerships to strengthen CDSCO’s mission, ensuring India remains a trusted pharma powerhouse for safe, effective care. Aims: This review explores CDSCOs structure, functions, workforce, testing labs, licensing, certifications, exports, and challenges, emphasizing its role in drug development and quality assurance, with a focus on 2024-2025 updates like biosimilars guidelines and the Uniform Code of Pharmaceutical Marketing Practices (UCPMP). Methods: This narrative review synthesizes insights from recent government reports, peer-reviewed journals, news outlets, and industry platforms, credible sources were synthesized, covering regulatory policy, pharmacovigilance, and API dependence, with cross-verification for accuracy in a narrative review format. Results: CDSCOs robust regulatory framework, supported by zonal and port offices, enforces good manufacturing practices and expands pharmacovigilance and testing infrastructure, aligning with global standards. However, reliance on Chinese APIs remains a challenge. Recommendations include AI-driven monitoring and local API production to strengthen Indias global pharmaceutical leadership.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- India’s pillars of trust: CDSCO’s role in drug development and quality assurance
- Date Crossref
- 01/10/2025
- Éditeur
- Comprehensive Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Seema Dental College and Hospital pays non établi dans la noticeUniversité ou école supérieure
-
All India Institute of Medical Sciences Rishikesh pays non établi dans la noticeOrganisme public
-
National Institute of Health and Family Welfare pays non établi dans la noticeOrganisme public
-
Master of Public Health (MPH) Scholar pays non établi dans la noticeInstitution
-
Deputy Medical Superintendent pays non établi dans la noticeInstitution
-
Professor Department of Biomedicine pays non établi dans la noticeInstitution
-
MD Community Medicine pays non établi dans la noticeInstitution
Seema Dental College and Hospital, All India Institute of Medical Sciences Rishikesh et National Institute of Health and Family Welfare, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.